Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 6/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497695 | 1.00 | DPP7 (0.50) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL21114423 | 1.00 | DPP7 (0.50) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL52379 | 0.92 | DPP7 (0.51) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL22418327 | 0.91 | GRIK1 (0.50) | DPP7SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL1484685 | 0.90 | GNAI3 (0.53) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL30287926 | 0.90 | DPP7 (0.46) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL17240909 | 0.90 | DPP7 (0.46) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL9243901 | 0.89 | DPP7 (0.48) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL27743403 | 0.89 | DPP7 (0.48) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL379284 | 0.89 | SLC15A1 (0.46) | DPP7SLC15A1SLC1A2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | DPP7 459/4885SLC15A1 3052/4885SLC1A2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.